Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21656333 | 0.85 | KMT2A (0.39) | KMT2AL3MBTL1 | |
| SCHEMBL21632014 | 0.84 | KMT2A (0.61) | KMT2AL3MBTL1FFAR1MTNR1AMTNR1B | |
| SCHEMBL1369506 | 0.84 | KMT2A (0.55) | KMT2AL3MBTL1FFAR1MTNR1AMTNR1B | |
| SCHEMBL21656570 | 0.84 | CTSL (0.43) | KMT2AFFAR1 | |
| SCHEMBL14996085 | 0.83 | CTSS (0.48) | KMT2AL3MBTL1TDP1 | |
| SCHEMBL8770863 | 0.82 | L3MBTL1 (0.66) | L3MBTL1MTNR1AMTNR1BCES2CES1 | |
| SCHEMBL2885762 | 0.81 | MTNR1A (0.54) | L3MBTL1FFAR1MTNR1AMTNR1BTDP1 | |
| SCHEMBL31326036 | 0.80 | KMT2A (0.70) | KMT2AL3MBTL1MTNR1AMTNR1BCES2 | |
| SCHEMBL2882501 | 0.79 | MTNR1A (0.49) | KMT2AL3MBTL1FFAR1MTNR1AMTNR1B | |
| SCHEMBL21656590 | 0.79 | L3MBTL1 (0.51) | L3MBTL1FFAR1MTNR1AMTNR1BAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-05 | — | — | US | disclosed |
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | AADAC, NAT1, EPX | KMT2A 921/4885L3MBTL1 3686/4885FFAR1 781/4885 |
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | AADAC, NAT1, EPX | KMT2A 921/4885L3MBTL1 3686/4885FFAR1 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.